Advertisement
Advertisement
U.S. Markets open in 5 hrs 1 min
Advertisement
Advertisement
Advertisement
Advertisement

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.92+0.03 (+0.38%)
At close: 04:00PM EDT
Advertisement
Sign in to post a message.
  • K
    Kaan
    ER is incoming.. what's your guess ?
    Bullish
  • 박
    fly high
    Bullish
  • Y
    Yahoo Finance Insights
    Amryt Pharma is up 8.27% to 8.38
  • 박
    Tell me if there's anyone who bought it. I'm bored
    Bullish
  • 박
    i wish good result
    Bullish
  • Y
    Yahoo Finance Insights
    Amryt Pharma is up 7.35% to 7.89
  • Y
    Yonatan
    Hi all ,
    I wanted to share my calculation and ask for advice or correction from more experienced people here.
    As for what I understand $CHMA was purchased by $AMYT based on the announcement today.
    Every CHMA stock will be converted to AMYT stock at a ration of 1:0.396 , hence every 5 CHMA stock will grant their owner 2 AMYT stocks.
    this process based on my understanding diluted AMYT stock price for the short term. hopefully the purchase will yield profits in the future but this is a gamble for the long run .
    for now there are 41.79M outstanding CHMA shares , that by ration of 0.396 will become 16.54M AYMT share.
    currently, AYMT has 35.88M shares outstanding , and in the end of the purchase will have 52.42M shares.
    35.88/52.42 = 0.6844
    hence the AYMT stock should be diluted around 32% for the short term.
    taking its value to be 13.5 based on last 3 months (pretty high but lets be optimistic) , the new value after dilution should be :
    13.5*0.68= 9.18$ a share.
    assuming the real value of AYMT did not change , not by assets or anything else.
    this is only math wise.

    is it right by far ?

    other considerations :
    a) CLAIM (cons) - The value might be lower than 9.18$ for the short term :
    As CHMA still not FDA approved, more money will need to be spent before any profit will come (at least 1-2 years) , hence the expenses grow at start which will drive the share price down at next reports.

    b) CLAIM (pro) - the price will be higher than 9.18$ , my estimate 10-11$ a share as the optimism is around, purchase is considered a good thing, to grow the business.... and this will translate into share price regardless of book value or with taking into account future revenues, at least at the short term.

    I cant see any justification not to sell my AMYT share now and buy them back again in 3 months time.

    any advice , correction to the above ?
    pls correct my logic if you think otherwise.

    thanks.
  • b
    bloodsport
    (CYTH) MCap $28 m--BIG Orphan Drug in Phase 3 & a Phase 2 Alzheimer Program = Sleeping GIANT with 10+ bagger opp
    https://cyclotherapeutics.com/wp-content/uploads/2021/12/CYTHPipe12.13B.png

    #
  • K
    Kaan
    This was my best buy. This is still my best buy. AND it's gonna get higher i hope
    Bullish
  • Y
    Yahoo Finance Insights
    Amryt Pharma is down 8.33% to 6.82
  • Y
    Yahoo Finance Insights
    Amryt Pharma is up 6.98% to 6.74
  • s
    steve
    Price drop is down to de-listing form the UK AIM market. This will cause a number of forced sales. Understand why, but could it not have been better handled?
  • F
    Faris
    PDUFA date under priority review November 30, 2021
    Bullish
  • C
    Chuck
    AMYT is raising revenue guidance for FY 2021 from prior guidance of between $210M - $215M to a range of $220M - $225M.
    Bullish
  • R
    Rustle Feathers
    average price target is $35. why are we still trading in 10-11 range?
  • C
    Chuck
    Buy rating with $45 price target.
    Bullish
  • y
    yaniv
    This is a holding company that has acquired a number of wonderful companies that are each worthwhile and have potential, I do not see the realization of synergy in products and certainly not in value
  • d
    decono1
    Snake oil bark extract
    Bearish
  • K
    Kaan
    We're running to EMA CHMP and PDUFA dates. Looking really good.
Advertisement
Advertisement